Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)
详细信息 查看全文
- 作者：K. Callis Duffin ; J. Bagel ; M. Bukhalo ; I.J. Mercado Clement ; S.L. Choi ; F. Zhao ; A. Gill ; B. Pangallo ; C. Shuler ; L. Mallbris and K. Jackson
- 刊名：Journal of the European Academy of Dermatology and Venereology
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：31
- 期：1
- 页码：107-113
- 全文大小：276K
- ISSN：1468-3083
文摘
The efficacy of ixekizumab, an anti-interleukin-17A (anti-IL-17A) monoclonal IgG4 antibody, was demonstrated in moderate-to-severe psoriasis patients when administered via prefilled syringe (PFS).